|Day's Range||2,398.00 - 2,508.35|
|52 Week Range||2,398.00 - 3,689.85|
|PE Ratio (TTM)||33.49|
|Earnings Date||Jul 24, 2017 - Jul 28, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||2,820.90|
NORTHVALE, N.J., May 22, 2017-- Elite Pharmaceuticals, Inc., today announced the acquisition of an approved and currently marketed Abbreviated New Drug Application for Trimipramine Maleate Capsules 25, ...
India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official. The lengthy timeline is a concern not only in India but around the world, as India's pharmaceutical firms supply a third of the drugs sold in the United States and a large percentage in other countries.
Dr. Reddy’s Laboratories Ltd. announced today that it has received approval from the U.S. Food and Drug Administration to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil® , for intravenous use, in the United States market.